Last reviewed · How we verify
Ropivacaine, Morphine
At a glance
| Generic name | Ropivacaine, Morphine |
|---|---|
| Sponsor | B.P. Koirala Institute of Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty (NA)
- Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients (PHASE4)
- PRO-RSTAP: Effect of TAP and RS Blocks on Recovery After Inguinal Hernia Surgery (PRO-RSTAP) (NA)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Observational Retrospective Study on Spinal Analgesia in Laparoscopic and Laparotomic Hysterectomy
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Intrathecal MoRphine Versus Transabdominal Plane Block (TAP) Block for AnalGesic Management in Elective Caesarean Section (PHASE4)
- Management of Pain Post Hepatectomy : Infiltration of Local Anesthetics Versus Continuous Spinal Analgesia . (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine, Morphine CI brief — competitive landscape report
- Ropivacaine, Morphine updates RSS · CI watch RSS
- B.P. Koirala Institute of Health Sciences portfolio CI